Lexicon Pharmaceuticals, Inc. LXRX
1.80
(0.06)
(3.23%)
as of 25 Sep
- Market cap
- $854.3M
- P/E
- 0.0×
Follow LXRX
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
6.92 | 8.38 | 8.97 | 25.33 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.58) | (24.23) | (42.39) | (114.27) | |
P/B ratio |
4.08 | 3.88 | 3.08 | 6.02 | |
Price to Tangible BV |
6.49 | 6.63 | 3.94 | 8.08 | |
EV/Sales |
6.68 | 7.54 | 7.29 | 22.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.56) | (5.53) | (13.09) | (14.09) | |
EV/FCF |
(6.47) | (5.45) | (12.75) | (13.87) | |
Quick Ratio |
5.45 | 4.73 | 18.43 | 13.07 | |
Current Ratio |
5.64 | 4.88 | 18.79 | 13.37 | |
Net Debt/EBITDA |
5.11 | 2.98 | 590.12 | 5.37 | |
Debt/Assets |
27.44% | 29.19% | 18.48% | 20.57% | |
Debt/Equity |
0.47 | 0.50 | 0.24 | 0.29 | |
Asset Turnover |
0.27 | 0.21 | 0.25 | 0.17 | |
Operating CF/Net income |
1.87 | 1.11 | 14.12 | 0.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
132.26% | 205.97% | 60.45% | 2,520.66% | |
Selling, General and Administrative Expense of Revenue |
53.60% | 159.46% | 43.76% | 1,408.96% | |
Intangible Assets out of Total Assets |
0.22 | 0.24 | 0.17 | 0.18 | |
Share Based Compensation of Revenue |
24.28% | 51.61% | 14.59% | 482.08% | |
Graham Net Nets |
0.07 | 0.06 | 0.19 | 0.12 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.07%) | (12.17%) | (4.65%) | (6.36%) | |
Free Cash Flow Yield |
(14.91%) | (16.50%) | (6.38%) | (6.29%) | |
Revenue per Share |
0.04 | 0.02 | 0.05 | 0.00 | |
Operating CF per Share |
(0.07) | (0.05) | (0.04) | (0.02) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.07) | (0.05) | (0.04) | (0.02) | |
Cash per Share |
0.32 | 0.27 | 0.43 | 0.44 | |
Shareholders Equity per Share |
0.33 | 0.30 | 0.51 | 0.40 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.33 | 0.30 | 0.51 | 0.40 | |
Free Cash Flow |
(23.83) | (17.23) | (14.73) | (9.19) | |
Working Capital |
100.81 | 81.03 | 176.13 | 181.87 | |
Net Current Asset Value |
36.76 | 24.45 | 120.07 | 121.04 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(90.04%) | (282.71%) | (4.94%) | (4,591.76%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
2.61 | 2.93 | 29.61 | 1.91 | |
Average Payables |
9.00 | 8.94 | 6.84 | 4.12 | |
Average Inventory |
0.40 | 0.26 | 0.24 | 0.68 | |
Average Assets |
263.53 | 241.70 | 283.25 | 237.82 | |
Average Common Equity |
149.34 | 126.74 | 162.94 | 151.98 |
Columns are period end dates